MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • 2022 International Congress

    Early Morning Dystonia in Parkinson’s Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I

    F. Stocchi, J. Ferreira, W. Poewe, O. Rascol, A. Antonini, J-F. Rocha (Rome, Italy)

    Objective: This study evaluated the effect of once-daily opicapone (OPC) 50 mg versus entacapone (ENT) on Early Morning Dystonia (EMD) in Parkinson’s disease patients with…
  • 2022 International Congress

    Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations

    G. Castilla-Fernández, M. Fonseca, J. Ferreira, J-F. Rocha (Coronado, Portugal)

    Objective: This study compared the effects of catechol-O-methyl transferase (COMT) inhibitors and monoamine oxidase‑B (MAO-B) inhibitors on mean change from baseline to end-of-study in OFF-time…
  • 2022 International Congress

    OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?

    F. Colucci, V. Rispoli, V. Tugnoli, M. Pugliatti, G. Tecilla, M. Sensi (Ferrara, Italy)

    Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…
  • 2022 International Congress

    The effect of co-administration of opicapone on the pharmacokinetics of levodopa

    D. Kamiyama, N. Nishikawa, G. Oyama, T. Hatano, N. Hattori (Tokyo, Japan)

    Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…
  • 2022 International Congress

    Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center

    E. Ojeda-Lepe, L. Muñoz-Delgado, S. Jesús, AD. Adarmes-Gómez, D. Macías-García, MV. Jiménez Jaraba, B. Benítez Zamora, F. Carrillo, P. Mir (Seville, Spain)

    Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…
  • MDS Virtual Congress 2021

    Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson’s Disease Patients

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study was designed to assess the effect of opicapone (OPC) 50 mg once daily (QD) on levodopa (L-DOPA) pharmacokinetics (PK) in different L-DOPA/carbidopa…
  • MDS Virtual Congress 2021

    The EON (Elderly patients on ONgentys) study in Parkinson’s disease: design and rationale of a prospective non-interventional trial

    V. Dostal, K. Chaudhuri, P. Odin, M. Kurtis, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Norwich, United Kingdom)

    Objective: To assess the tolerability of opicapone (OPC) when used in elderly patients with Parkinson’s disease (PD) in real-world conditions. Background: OPC proved to be…
  • MDS Virtual Congress 2021

    Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To assess the influence of a 6-month treatment with opicapone (OPC) on the costs for the care of Parkinson’s disease (PD) patients. Background: OPC…
  • MDS Virtual Congress 2021

    Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…
  • MDS Virtual Congress 2021

    Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data

    M. Mata Alvarez-Santullano, C. Borrue Fernández, CM. Labandeira Guerra, T. Muñoz Ruiz, J. Abril Jamarillo, V. Gómez Mayordomo, PE. Bermejo Velasco (San Sebastián Reyes, Spain)

    Objective: To evaluate the efficacy and tolerability of opicapone in patients in Parkinson’s disease (PD) patients with early/simple motor fluctuations (E/S-MF) in the Spanish clinical…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29509 (not found)
  • #22661 (not found)
  • #25945 (not found)
  • #23027 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley